TCRX Key Statistics, Chart & Performance
The current stock price of TCRX is 0.96 USD. In the past month the price decreased by -15.67%. In the past year, price decreased by -55.9%.
TCRX Technical Analysis
TCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRX. The financial health of TCRX is average, but there are quite some concerns on its profitability.
TCRX Financial Highlights
Over the last trailing twelve months TCRX reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS decreased by -5.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.38% | ||
| ROE | -99.01% | ||
| Debt/Equity | 0.23 |
TCRX Forecast & Estimates
13 analysts have analysed TCRX and the average price target is 7.14 USD. This implies a price increase of 643.75% is expected in the next year compared to the current price of 0.96.
For the next year, analysts expect an EPS growth of 4.68% and a revenue growth 207.63% for TCRX
TCRX Ownership
TCRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.04 | 383.716B | ||
| AMGN | AMGEN INC | 16.23 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.75 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.71 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.14 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 11.99 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCRX
Company Profile
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Company Info
TSCAN THERAPEUTICS INC
830 Winter Street
Waltham MASSACHUSETTS US
CEO: David Southwell
Employees: 2
Phone: 18573999500
TSCAN THERAPEUTICS INC / TCRX FAQ
What does TSCAN THERAPEUTICS INC do?
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
What is the stock price of TSCAN THERAPEUTICS INC today?
The current stock price of TCRX is 0.96 USD.
Does TSCAN THERAPEUTICS INC pay dividends?
TCRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TCRX stock?
TCRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is TSCAN THERAPEUTICS INC (TCRX) expected to grow?
The Revenue of TSCAN THERAPEUTICS INC (TCRX) is expected to grow by 207.63% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for TSCAN THERAPEUTICS INC?
TSCAN THERAPEUTICS INC (TCRX) will report earnings on 2026-03-04, after the market close.
Can you provide the ownership details for TCRX stock?
You can find the ownership structure of TSCAN THERAPEUTICS INC (TCRX) on the Ownership tab.